Evan Seigerman
Stock Analyst at BMO Capital
(3.32)
# 371
Out of 5,182 analysts
154
Total ratings
54.9%
Success rate
13.19%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $147 → $140 | $127.68 | +9.65% | 16 | Feb 12, 2026 | |
| BIIB Biogen | Maintains: Market Perform | $165 → $196 | $184.38 | +6.30% | 28 | Feb 9, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $52.89 | +2.10% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $883.96 | +35.75% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $130.40 | -0.31% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $430.29 | +23.17% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $94.65 | -36.61% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $68.85 | +74.29% | 6 | May 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $58.71 | +3.90% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $45.49 | -12.07% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $2.42 | +1,552.89% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $751.57 | +4.85% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $4.89 | -48.88% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $344.55 | -29.47% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $6.50 | +84.62% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $27.00 | +122.22% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $3.19 | +840.44% | 3 | May 12, 2020 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Market Perform
Price Target: $147 → $140
Current: $127.68
Upside: +9.65%
Biogen
Feb 9, 2026
Maintains: Market Perform
Price Target: $165 → $196
Current: $184.38
Upside: +6.30%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $52.89
Upside: +2.10%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $883.96
Upside: +35.75%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $130.40
Upside: -0.31%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $430.29
Upside: +23.17%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $94.65
Upside: -36.61%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $68.85
Upside: +74.29%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $58.71
Upside: +3.90%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $45.49
Upside: -12.07%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $2.42
Upside: +1,552.89%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $751.57
Upside: +4.85%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $4.89
Upside: -48.88%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $344.55
Upside: -29.47%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $6.50
Upside: +84.62%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $27.00
Upside: +122.22%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $3.19
Upside: +840.44%